盐酸替罗非班在ST段抬高急性心肌梗死治疗中的临床应用效果分析

Analysis of the Clinical Application Effect of Tirofiban Hydrochloride in the Treatment of ST-segment Elevation Acute Myocardial Infarction

目的探讨对ST段抬高急性心肌梗死患者采用盐酸替罗非班药物进行治疗后获得临床效果。方法随机选取2018年1月—2020年12月该院收治的100例ST段抬高急性心肌梗死患者进行治疗研究,随机分为参照组(常规治疗)和研究组(常规治疗+盐酸替罗非班治疗),各50例。比较两组患者用药总有效率、不良事件(再发心绞痛、恶性心律失常、再梗死)总发生率、心功能指标[左室收缩末期内径(LVESD)、左心室射血分数(LVEF)以及6 min步行试验(6MWT)]以及ST段回落率。结果研究组治疗总有效率(96.00%)高于参照组(76.00%),差异有统计学意义(χ^(2)=8.306,P<0.05);研究组不良事件(再发心绞痛、恶性心律失常、再梗死)总发生率(4.00%)低于参照组(24.00%),差异有统计学意义(χ^(2)=8.306,P<0.05);治疗前,研究组LVESD(45.21±2.29)mm、LVEF(36.22±3.15)%以及6MWT(227.39±32.73)m同参照组LVESD(45.33±2.32)mm、LVEF(35.31±3.29)%以及6MWT(225.69±31.82)m比较,差异无统计学意义(t=0.260、1.412、0.263,P>0.05);治疗后,研究组LVESD(31.36±3.31)mm、LVEF(53.39±4.29)%以及6MWT(319.39±22.17)m分别低于、高于以及长于参照组LVESD(36.32±3.19)mm、LVEF(48.29±3.63)%以及6MWT(275.21±21.39)m,差异有统计学意义(t=7.629、6.417、10.140,P<0.05);研究组ST段总回落率(96.00%)高于参照组(74.00%),差异有统计学意义(χ^(2)=9.490,P<0.05)。结论盐酸替罗非班药物有效应用后,患者用药总有效率、不良事件总发生率、心功能指标以及ST段回落率,均获得明显改善,可促进ST段抬高急性心肌梗死患者总体用药效果、预后效果双重提升。

Objective To explore the clinical effects of Tirofiban hydrochloride in patients with ST-segment elevation acute myocardial infarction.Methods A total of 100 patients with ST-segment elevation acute myocardial infarction admitted the hospital from January 2018 to December 2020 were randomly selected for the treatment study,and randomly divided into the reference group(conventional treatment)and the study group(conventional treatment+tirofiban hydrochloride treatment),50 cases in each group.The total effective rate,the total incidence of adverse events(recurrent angina,malignant arrhythmia,reinfarction),cardiac function indicators[left ventricular end systolic diameter(LVESD),left ventricular ejection fraction(LVEF)and 6-min walking test(6MWT)]and ST segment regression rate were compared between two groups.Results The total effective rate of the study group(96.00%)was higher than that of the reference group(76.00%),the difference was statistically significant(χ^(2)=8.306,P<0.05).The overall incidence of adverse events(recurrent angina,malignant arrhythmia,reinfarction)in the study group(4.00%)was lower than that in the reference group(24.00%),the difference was statistically significant(χ^(2)=8.306,P<0.05).Before the treatment,the LVESD(45.21±2.29)mm,LVEF(36.22±3.15)%and 6MWT(227.39±32.73)m in the study group were the same as those in the reference group(35.31±3.29)%and 6MWT(225.69±31.82)m.The difference was not statistically significant(t=0.260,1.412,0.263,P>0.05).After treatment,the LVESD(31.36±3.31)mm,LVEF(53.39±4.29)%and 6MWT(319.39±22.17)m in the study group were lower,higher and longer than those in the reference group(36.32±3.19)mm,(48.29±3.63)%and 6MWT(275.21±21.39)m,the difference was statistically significant(t=7.629,6.417,10.140,P<0.05).The total ST segment regression rate in the study group(96.00%)was higher than that in the reference group(74.00%),the difference was statistically significant(χ^(2)=9.490,P<0.05).Conclusion After the effective application of tirofiban hydrochloride,the total effective rate of medication,the total incidence of adverse events,the index of heart function,and the rate of ST-segment fall were significantly improved.It can promote the dual improvement of the overall medication effect and prognosis of patients with ST-segment elevation acute myocardial infarction.